argenx SE entered a definitive agreement to acquire Forte Biosciences, Inc. for approximately $2.2 billion. The transaction, structured as a cash tender offer, values Forte Biosciences at $77 per share. The acquisition aims to add FB102, an anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, to argenx's immunology pipeline. The deal is expected to close in Q3 2026, subject to customary closing conditions and regulatory approvals. argenx will fund the acquisition entirely from cash on hand. argenx is a global immunology innovation company that develops antibody-based medicines for autoimmune diseases.

argenx SE reported strong second quarter 2026 financial results, with product net sales reaching $1.5 billion, a 60% increase year-over-year. The company achieved an operating profit of $494 million for the quarter, compared to $201 million in the prior-year period. Net profit for the three months ended June 30, 2026, was $472 million, resulting in a basic profit per share of $7.58. Growth was driven by the expanded VYVGART label in the U.S. to include all gMG serotypes. Total cash, cash equivalents, and current financial assets stood at $5.2 billion as of June 30, 2026. The company is an immunology innovation company developing antibody-based medicines for autoimmune diseases.